Literature DB >> 24944792

Differential expression of CRKL and AXL genes in lung adenocarcinoma subtypes according to the epidermal growth factor receptor and anaplastic lymphoma kinase gene status.

DA-Ping Yu1, Yu-Jie Dong2, Hai-Qing Zhang2, Jing-Hui Wang3, Yang Qu2, Li-Juan Zhou2, Dan Su2, Li-Li Zhang2, Dan Zhao2, Yi-Ran Cai2.   

Abstract

Non-small-cell lung cancer (NSCLC) is the most common cause of cancer-related mortality. Adenocarcinoma (AC) is the predominant histological type of NSCLC; however, AC consists of several subtypes. It has not yet been determined whether there is a correlation of CRKL and AXL expression with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene status in lung AC. We assayed exons 18 through 21 of the EGFR gene by direct sequencing; ALK rearrangement and the expression of CRKL and AXL were detected by immunostaining. A total of 212 cases of AC were included in this study, diagnosed using the novel classification system established by the International Association for the Study of Lung Cancer, the American Thoracic Society and the European Respiratory Society in 2011, including 69 acinar ACs, 17 lepidic predominant ACs (LPAs), 63 papillary, 14 mucinous, 17 micropapillary and 32 solid ACs. Of the 212 cases, 101 harbored EGFR mutations. The most common subtypes carrying delK745-S753 were papillary and acinar ACs. ALK rearrangement was found in 23 cases (11%) of lung ACs. Acinar and solid ACs were the most frequent subtypes with ALK aberrance, particularly in acinar ACs with cribriform structure (4/5 cases, 80%). The expression of CRKL was significantly different among the AC subtypes (P=0.01), with the highest and lowest expression levels of CRKL protein in papillary ACs and LPAs, respectively (P<0.05). AXL expression was also significantly different among the AC subtypes (P=0.002) and was correlated with lymph node infiltration in acinar ACs. ACs with EGFR mutations exhibited high levels of AXL protein expression compared to those without mutations (P<0.001). Acinar AC with cribriform structure is a distinct subtype that frequently harbors ALK rearrangement. The activation of AXL may be one of the factors contributing to the invasion of acinar and micropapillary ACs.

Entities:  

Keywords:  AXL; CRKL; anaplastic lymphoma kinase gene rearrangement; epidermal growth factor receptor gene mutation; lung adenocarcinoma

Year:  2014        PMID: 24944792      PMCID: PMC4051477          DOI: 10.3892/br.2014.261

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  42 in total

1.  A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.

Authors:  Mari Mino-Kenudson; Lucian R Chirieac; Kenny Law; Jason L Hornick; Neal Lindeman; Eugene J Mark; David W Cohen; Bruce E Johnson; Pasi A Jänne; A John Iafrate; Scott J Rodig
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

2.  Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.

Authors:  Kazuko Sakai; Tokuzo Arao; Tatsu Shimoyama; Kimiko Murofushi; Masaru Sekijima; Naoko Kaji; Tomohide Tamura; Nagahiro Saijo; Kazuto Nishio
Journal:  FASEB J       Date:  2005-12-22       Impact factor: 5.191

3.  The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.

Authors:  Alvarez Hector; Elizabeth A Montgomery; Collins Karikari; Marcia Canto; Kerry B Dunbar; Jean S Wang; Georg Feldmann; Seung-Mo Hong; Michael C Haffner; Alan K Meeker; Sacha J Holland; Jiaxin Yu; Thilo J Heckrodt; Jing Zhang; Pingyu Ding; Dane Goff; Rajinder Singh; Juan Carlos Roa; Arivusudar Marimuthu; Gregory J Riggins; James R Eshleman; Barry D Nelkin; Akhilesh Pandey; Anirban Maitra
Journal:  Cancer Biol Ther       Date:  2010-11-15       Impact factor: 4.742

4.  Axl, a novel receptor tyrosine kinase isolated from chronic myelogenous leukemia.

Authors:  A Neubauer; J P O'Bryan; A Fiebeler; C Schmidt; D Huhn; E T Liu
Journal:  Semin Hematol       Date:  1993-07       Impact factor: 3.851

5.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

6.  Expression of MET and SOX2 genes in non-small cell lung carcinoma with EGFR mutation.

Authors:  Yi-Ran Cai; Hai-Qing Zhang; Yang Qu; Jing Mu; Dan Zhao; Li-Juan Zhou; Hong Yan; Jian-Wei Ye; Yan Liu
Journal:  Oncol Rep       Date:  2011-06-15       Impact factor: 3.906

7.  Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung.

Authors:  Young Hak Kim; Genichiro Ishii; Koichi Goto; Kanji Nagai; Koji Tsuta; Satoshi Shiono; Junichi Nitadori; Testuro Kodama; Yutaka Nishiwaki; Atsushi Ochiai
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

8.  Proposal of an improved histological sub-typing system for lung adenocarcinoma - significant prognostic values for stage I disease.

Authors:  Koji Okudela; Tetsukan Woo; Hideaki Mitsui; Takuya Yazawa; Hiroaki Shimoyamada; Michihiko Tajiri; Nobuo Ogawa; Munetaka Masuda; Hitoshi Kitamura
Journal:  Int J Clin Exp Pathol       Date:  2010-03-25

9.  Lung adenocarcinoma as a solitary pulmonary nodule: prognostic determinants of CT, PET, and histopathologic findings.

Authors:  Ho Yun Lee; Joungho Han; Kyung Soo Lee; Ji Hyun Koo; Sun Young Jeong; Byung-Tae Kim; Young-Seok Cho; Young Mog Shim; Jhingook Kim; Kwanmien Kim; Yong Soo Choi
Journal:  Lung Cancer       Date:  2009-03-18       Impact factor: 5.705

10.  Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.

Authors:  Noriko Motoi; Janos Szoke; Gregory J Riely; Venkatraman E Seshan; Mark G Kris; Valerie W Rusch; William L Gerald; William D Travis
Journal:  Am J Surg Pathol       Date:  2008-06       Impact factor: 6.394

View more
  2 in total

1.  Association between the histological subtype of lung adenocarcinoma, EGFR/KRAS mutation status and the ALK rearrangement according to the novel IASLC/ATS/ERS classification.

Authors:  Yu-Jie Dong; Yi-Ran Cai; Li-Juan Zhou; Dan Su; Jing Mu; Xue-Jing Chen; L I Zhang
Journal:  Oncol Lett       Date:  2016-02-17       Impact factor: 2.967

Review 2.  Axl as a mediator of cellular growth and survival.

Authors:  Haley Axelrod; Kenneth J Pienta
Journal:  Oncotarget       Date:  2014-10-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.